

POSITION STATEMENT

PSG Executive Committee

Michael Schwarzschild, MD, PhD, Chair & Hubert Fernandez, MD, Co-Chair

Our Vision Statement: PSG 2012-2018

Our Vision: *Over the period of our term, the PSG will...*

... make substantial advances in our understanding and treatment of Parkinson's disease and other parkinsonian disorders, as an efficient, collaborative network of talented clinicians and scientists, operating under a supportive and proactive leadership with broad backing from government, industry, foundation and patient stake-holders in the Parkinson community.

Our Overarching Aims:

- I. Expand and diversify the portfolio of PSG studies
- II. Increase the value of a PSG Membership to better engage members
- III. Prepare the PSG for the next 25 Years

Our Specific Strategies:

I. Expand and diversify the portfolio of PSG Studies

A. Reestablish industry-sponsored clinical trials

1. Reengage industry sponsors and effectively articulate 'the PSG advantage' of high quality network, expertise and neutrality
2. Establish task force to accelerate industry outreach through individual and collective/retreat presentations, scientific symposia, exchange at Annual Meeting.
3. Incentivize member outreach to industry, affirming ability to serve as PIs and Co-PIs and on SCs, with appropriate percent efforts, while maintaining high PSG Conflict of Interest standards.

B. Maintain and expand federal- and foundation-sponsored studies

1. By policy, programs and example, encourage more investigator-initiated projects.
2. Expand foundation collaborations (PDF/PSG awards, Fox/DATATOP programs)

C. Build collaborations with other PD/Movement Disorders study groups, non-profits

1. Team up with PD foundations and related study groups (HSG, Cure PSP, etc) in developing joint projects, educational events, public position statements, etc.
2. Continue to cultivate collaborations with PD Consortia/Networks around the globe (China, Sweden/Scandinavia, India, Germany, etc)

II. Increase the value of PSG Membership and Reengage its members and centers

A. Provide more PSG sites with more high quality study opportunities (via IA→IC above).

B. Ensure a standardized site selection process based on merit, fairness and transparency.

C. Reevaluate the PSG Annual Meeting yearly (e.g., via Membership survey), restructuring (as warranted) to ensure coordinators' as well as investigators' needs are met; and incorporating sessions that cultivate internal and external collaborations

- D. Further enhance the PSG website functionality for members, and working groups/committees, institutional/private funders, patients (trial subjects).
 - 1. Make the website the central hub of communication for PSG task forces, committees and initiatives.
 - 2. Add portal for potential industry partners and other funding agencies to highlight ‘the PSG advantage’ (as above), collective experience of Members and sites.
 - 3. Develop webpages for active PSG studies for staff, subjects and public/media.
 - 4. Provide PD community services – research newsfeeds and/or links to other PD sites (trial finders, foundations, patient-run sites/NorthwestPF, PAN, MDS, etc).
- E. Clarify and articulate to the Membership the “pathways” to PSG study development.
- F. Consider adding an elected junior investigator (within 5 years of fellowship) member position to the Executive Committee for 1 year terms, providing valuable early career experiences as well as a fresh perspective to the EC.

III *Prepare the PSG for the next 25 years*

- 1. Invest in junior members—the next generation of clinicians and scientists.
- 2. Expand the PSG to include other parkinsonian conditions.
- 3. Invest and utilize technology in improving the PSG network and conducting clinical trials.
- 4. Solidify the PSG Structure (i.e. secretariat, coordination center, and its various “cores”).
- 5. Work towards a positive financial state.